Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Report 2026

Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Overview

• Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics market size has reached to $8.43 billion in 2025 • Expected to grow to $11.04 billion in 2030 at a compound annual growth rate (CAGR) of 5.5% • Growth Driver: Rising Prevalence Of Prostate Cancer Fueling The Growth Of The Market Due To Aging Population And Increasing Case Numbers • Market Trend: Dual Action Tablets Gain FDA Approval To Boost Treatment Outcomes In Resistant Prostate Cancer • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?

Castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics are drugs and treatments used for castration-resistant prostate cancer (CRPC), an advanced form of prostate cancer that continues to progress despite the lowering of testosterone levels, usually after androgen deprivation therapy. These therapeutics aim to overcome resistance mechanisms, improving patient outcomes and extending survival. The main therapy types of castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics are hormonal therapy, chemotherapy, immunotherapy, targeted therapy, and radiation therapy. Hormonal therapy refers to the treatment that uses hormones or hormone-blocking drugs to slow down or stop the growth of hormone-sensitive diseases, such as certain cancers. These are administered through oral, injectable, and intravenous routes, serving a range of end users, including hospitals, oncology centers, ambulatory surgical centers, and others.

What Is The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Growth Forecast?

The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market size is expected to see strong growth in the next few years. It will grow to $11.04 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to biomarker-driven treatment, advanced targeted therapies, oral oncology adoption, oncology pipeline expansion, personalized cancer care. Major trends in the forecast period include rising use of androgen receptor inhibitors, growth of parp inhibitor therapies, expansion of combination treatment regimens, increased focus on precision oncology, shift toward oral oncology drugs.

Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Segmentation

1) By Therapy Type: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy 2) By Route Of Administration: Oral, Injectable, Intravenous 3) By End User: Hospitals, Oncology Centers, Ambulatory Surgical Centers, Other End Users Subsegments: 1) By Hormonal Therapy: Androgen Receptor (AR) Inhibitors, Androgen Synthesis Inhibitors, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Or Antagonists, Gonadotropin-Releasing Hormone (GnRH) Agonists Or Antagonists 2) By Chemotherapy: Taxanes, Platinum-Based Agents, Other Chemotherapies 3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines 4) By Targeted Therapy: Poly ADP-Ribose Polymerase (PARP) Inhibitors, Phosphoinositide 3-Kinase (PI3K) Or Protein Kinase B (PI3K) Or Mammalian Target Of Rapamycin (mTOR) Inhibitors, Tyrosine Kinase Inhibitors (TKIs), Deoxyribonucleic Acid Damage Response (DDR) Inhibitors 5) By Radiation Therapy: External Beam Radiation Therapy, Brachytherapy, Radiopharmaceuticals

What Is The Driver Of The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?

The rising prevalence of prostate cancer is expected to propel the growth of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market going forward. Prostate cancer refers to a type of cancer that develops in the prostate gland, a small gland in men located below the bladder and in front of the rectum. The rising prevalence of prostate cancer is due to the aging population, as the risk of developing prostate cancer increases significantly with age. Castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics help in treating prostate cancer by targeting advanced stages of the disease that no longer respond to conventional hormone therapy. They improve patient outcomes by slowing disease progression and managing symptoms, thereby enhancing quality of life. For instance, in October 2025, according to NHS Digital, a UK-based government agency responsible for healthcare data and statistics, there were 58,137 new diagnoses of prostate cancer in England in 2023, representing a 6 percent increase compared with 2022. Therefore, the rising prevalence of prostate cancer is driving the growth of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics industry.

Key Players In The Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

Major companies operating in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market are Pfizer Inc., Johnson And Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Lantheus Holdings Inc., POINT Biopharma Global Inc., Clovis Oncology Inc., Arvinas Inc., Clarity Pharmaceuticals Ltd, Modra Pharmaceuticals B.V., Oncternal Therapeutics Inc., Zenith Epigenetics Ltd., ESSA Pharma Inc.

Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Trends and Insights

Major companies operating in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market are focusing on developing innovative products and getting approvals, such as dual-action tablets, to enhance treatment efficacy and patient outcomes. Dual-action tablets refer to advanced formulations that combine two therapeutic agents in a single dose to simultaneously target multiple pathways in castration-resistant prostate cancer (CRPC) treatment. For instance, in August 2023, Janssen Pharmaceuticals, a Belgium-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Akeega, a novel tablet developed for the treatment of adults with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Akeega is a precision medicine that combines a PARP inhibitor (niraparib) with a CYP17 inhibitor (abiraterone acetate), specifically targeting patients with BRCA mutations. When used alongside prednisone, it significantly enhances radiographic progression-free survival (rPFS) compared to conventional hormonal therapy alone.

What Are Latest Mergers And Acquisitions In The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?

In June 2024, AstraZeneca plc, a US-based pharmaceutical company, acquired Fusion Pharmaceuticals Inc. for an undisclosed amount. With this acquisition, AstraZeneca aims to transform cancer treatment and outcomes by replacing traditional chemotherapy and radiotherapy with more targeted next-generation radioconjugate therapies. Fusion Pharmaceuticals Inc. is a Canada-based biotech company that is actively developing FPI-2265, a targeted alpha therapy, for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Regional Insights

North America was the largest region in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?

The castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market consists of sales of enzalutamide, darolutamide, abiraterone, and cabazitaxel. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Report 2026?

The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.